OLGA and OLGIM Stage System for Gastric Cancer

Seoul National University

Status: Completed

Conditions: Atrophic Gastritis; Intestinal Metaplasia; Stomach Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT03380052

B-1610/368-106

Details and patient eligibility

About

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

Full description

To validated the OLGA and OLGIM staging system with serum pepsinogen to estimate gastric cancer risk according to Lauren's histologic classification in South Korea, where the incidence rate of GC is high. In addition, the investigators attempted to investigate the interaction among the several risk factors including OLGA or OLGIM staging system for the risk of GC to help establish surveillance strategy.

Enrollment: 2,900 patients

Sex: All

Ages: 25 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Control group

  • those who were between 25 and 80 years old and did not have any evidence of gastric cancer and gastric dysplasia, esophageal tumor and MALToma in upper gastrointestinal endoscopy

• Gastric cancer group

  • Patients diagnosed as gastric cancer in the upper gastrointestinal endoscopy at the time of participating in the study between 25 and 80 years old.

Exclusion criteria

• history of previous gastrointestinal surgery,
• any other malignancy
• cardia cancer
• who do not perform endoscopic biopsy
• pathologically proven gastric dysplasia

Trial design

2,900 participants in 2 patient groups

Gastric cancer

Description:

Patients who were diagnosed with gastric cancer

Control

Description:

Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease